Lung Cancer Survival and Ethnicity
What could possibly make death rates for foreign- and U.S.-born Hispanics with lung cancer patients different? Well, it’s not genetic differences, so what could it be?
One Large Step in the Small-Cell Lung Cancer Journey
There are two major types of lung cancer. The most common type is called non-small cell lung cancer. Small cell lung cancer makes up only about 15 percent of the 226,000 cases of lung cancer diagnosed in the US every year. New treatments for this more aggressive lung cancer may be on the horizon.
Pfizer Drug Receives Positive Opinion for Lung Cancer
Pfizer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that crizotinib be granted conditional marketing authorization in the European Union (EU).
Pfizer Announces Positive Results From Xalkori Trial
Pfizer Inc. announced today that the PROFILE 1007 study demonstrated that XALKORI ( crizotinib ) significantly improved progression-free survival ( PFS ) when compared with pemetrexed or docetaxel , in previously treated patients with anaplastic lymphoma kinase ( ALK )-positive advanced non-small cell lung cancer ( NSCLC ).
Are Two Cancer Drugs Better Than One?
Recent trends in cancer research have focused on combination therapies, where drugs that supplement each other's weaknesses show greater results in fighting cancer than either would alone.
Upcoming Lung Cancer Drugs
Out of the top five most common cancers, lung cancer is projected to remain the deadliest, and it isn't just limited to people who smoke.
Big Tumors Vulnerable to Chemo
Chemotherapy is generally recommended for cancers where surgery is impossible, either due to metastasis, difficult location, or small size.
Double Down on Lung Cancer Treatment
Lung cancer, prostate cancer, and breast cancer have roughly equal numbers of new cases diagnosed each year, but lung cancer is four times as fatal than the other two.
"Hispanic Paradox" Extends to Lung Cancer
Hispanic cancer patients tend to outlive white or black patients with the same disease. This phenomenon is known as "The Hispanic Paradox."
Chemotherapy not Effective in Seniors?
Cancer treatment has come a long way in the last few decades, and further refinement is a constant process. New research shows that the age of the patient may influence the best drug treatment option.